Dishman Carbogen Amcis Past Earnings Performance
Past criteria checks 0/6
Dishman Carbogen Amcis's earnings have been declining at an average annual rate of -63.1%, while the Life Sciences industry saw earnings growing at 15.8% annually. Revenues have been growing at an average rate of 5.6% per year.
Key information
-63.1%
Earnings growth rate
-62.8%
EPS growth rate
Life Sciences Industry Growth | 11.2% |
Revenue growth rate | 5.6% |
Return on equity | -4.4% |
Net Margin | -10.3% |
Next Earnings Update | 13 Nov 2024 |
Recent past performance updates
Recent updates
The Market Doesn't Like What It Sees From Dishman Carbogen Amcis Limited's (NSE:DCAL) Revenues Yet
Oct 15Why Investors Shouldn't Be Surprised By Dishman Carbogen Amcis Limited's (NSE:DCAL) 31% Share Price Plunge
Jun 01Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Feb 25Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt
Dec 29Is Dishman Carbogen Amcis (NSE:DCAL) Using Too Much Debt?
Jun 22Is Dishman Carbogen Amcis (NSE:DCAL) A Risky Investment?
Feb 14Dishman Carbogen Amcis (NSE:DCAL) Use Of Debt Could Be Considered Risky
Jun 22Shareholders Will Be Pleased With The Quality of Dishman Carbogen Amcis' (NSE:DCAL) Earnings
May 18Dishman Carbogen Amcis (NSE:DCAL) Has A Pretty Healthy Balance Sheet
Mar 14We Think Dishman Carbogen Amcis (NSE:DCAL) Is Taking Some Risk With Its Debt
Aug 23Why Dishman Carbogen Amcis Limited (NSE:DCAL) Could Be Worth Watching
Apr 29Dishman Carbogen Amcis (NSE:DCAL) Has A Somewhat Strained Balance Sheet
Mar 16A Look At Dishman Carbogen Amcis' (NSE:DCAL) Share Price Returns
Feb 23How Much Are Dishman Carbogen Amcis Limited (NSE:DCAL) Insiders Spending On Buying Shares?
Feb 05Is Dishman Carbogen Amcis Limited (NSE:DCAL) Popular Amongst Institutions?
Jan 23What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation
Jan 10Is Now An Opportune Moment To Examine Dishman Carbogen Amcis Limited (NSE:DCAL)?
Dec 23Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt
Dec 05Dishman Carbogen Amcis Limited (NSE:DCAL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Nov 17If You Had Bought Dishman Carbogen Amcis' (NSE:DCAL) Shares Three Years Ago You Would Be Down 47%
Oct 23What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation
Sep 27Is Now The Time To Look At Buying Dishman Carbogen Amcis Limited (NSE:DCAL)?
Sep 06Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Could Signal Some Risk
Aug 03Dishman Carbogen Amcis Limited's (NSE:DCAL) Price In Tune With Earnings
Jul 20Market Cool On Dishman Carbogen Amcis Limited's (NSE:DCAL) Earnings
Jul 06Revenue & Expenses Breakdown
How Dishman Carbogen Amcis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 24,162 | -2,480 | 12,299 | 0 |
31 Mar 24 | 26,158 | -1,534 | 12,161 | 0 |
31 Dec 23 | 25,796 | -1,542 | 11,510 | 0 |
30 Sep 23 | 25,683 | -477 | 11,147 | 0 |
30 Jun 23 | 25,957 | -168 | 10,752 | 0 |
31 Mar 23 | 24,129 | -298 | 10,382 | 0 |
31 Dec 22 | 23,634 | -37 | 10,452 | 0 |
30 Sep 22 | 22,856 | -152 | 10,300 | 0 |
30 Jun 22 | 21,306 | 60 | 9,988 | 0 |
31 Mar 22 | 21,407 | 180 | 9,889 | 0 |
31 Dec 21 | 21,013 | -724 | 9,580 | 0 |
30 Sep 21 | 20,078 | -1,239 | 9,273 | 0 |
30 Jun 21 | 19,884 | -1,277 | 9,072 | 0 |
31 Mar 21 | 19,120 | -1,651 | 8,822 | 0 |
31 Dec 20 | 18,946 | 419 | 8,640 | 0 |
30 Sep 20 | 19,683 | 908 | 8,322 | 0 |
30 Jun 20 | 19,961 | 1,246 | 7,924 | 0 |
31 Mar 20 | 20,436 | 1,585 | 7,720 | 0 |
31 Dec 19 | 21,812 | 1,837 | 8,228 | 0 |
30 Sep 19 | 21,179 | 2,022 | 8,086 | 0 |
30 Jun 19 | 20,983 | 2,050 | 7,361 | 0 |
31 Mar 19 | 20,586 | 2,103 | 7,718 | 0 |
31 Dec 18 | 18,924 | 1,862 | 7,331 | 0 |
30 Sep 18 | 18,745 | 1,768 | 7,132 | 0 |
30 Jun 18 | 18,826 | 1,812 | 6,541 | 0 |
31 Mar 18 | 16,948 | 1,546 | 6,766 | 0 |
31 Dec 17 | 17,854 | 1,537 | 6,844 | 0 |
30 Sep 17 | 16,840 | 1,383 | 6,568 | 0 |
30 Jun 17 | 16,778 | 1,282 | 5,944 | 0 |
31 Mar 17 | 17,194 | 1,454 | 6,496 | 0 |
31 Dec 16 | 12,038 | 953 | 4,240 | -35 |
31 Mar 16 | 68 | 9 | 51 | 0 |
31 Mar 15 | 0 | -5 | 0 | 0 |
Quality Earnings: DCAL is currently unprofitable.
Growing Profit Margin: DCAL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DCAL is unprofitable, and losses have increased over the past 5 years at a rate of 63.1% per year.
Accelerating Growth: Unable to compare DCAL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DCAL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (32.8%).
Return on Equity
High ROE: DCAL has a negative Return on Equity (-4.41%), as it is currently unprofitable.